Lundbeck, Otsuka collborate on Alzheimer's

Share this article:

Lundbeck and Otsuka are working together on a vaccine to combat Alzheimer's disease. This would be the duo's third Alzheimer's collaboration, and the agreement tethers the companies through Phase I.

This effort is an anti-beta amyloid vaccine that the companies expect would be used in the elderly. The companies said in a statement that the idea behind the treatment is that it could preserve cognitive function by preventing amyloid-beta deposits from accumulating.

The companies will decide next steps when Phase I ends. They expect the study to start next year.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.